(Q37794466)

23 August 2017

Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease (English)

1 reference

23 August 2017

0 references

0 references

1 reference

1 reference

1 reference

cognitive dysfunction

1 reference

Roger A Barker

2

0 references

Trevor W. Robbins

object named as

Trevor W Robbins

series ordinal

3

0 references

Angie A Kehagia

series ordinal

1

object named as

Angie A Kehagia

1 reference

23 August 2017

27 September 2010

1 reference

23 August 2017

1 reference

23 August 2017

9

1 reference

23 August 2017

12

1 reference

23 August 2017

1200-1213

1 reference

SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders

23 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

The morbid anatomy of dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Staging of brain pathology related to sporadic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Epidemiology of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

The association of incident dementia with mortality in PD.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

An essay on the shaking palsy. 1817.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Memory and executive function impairment predict dementia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Neuropsychological prediction of dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Neuropsychological profile of patients with Parkinson's disease without dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Defining mild cognitive impairment in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Fronto-striatal cognitive deficits at different stages of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Planning and spatial working memory in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

The neuropsychology of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Internal versus external cues and the control of attention in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Self-initiated versus externally triggered movements

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Switching between abstract rules reflects disease severity but not dopaminergic status in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Quality of life in Parkinson's disease: the relative importance of the symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Determinants of disability and quality of life in mild to moderate Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Predictors of health status in nondepressed and nondemented individuals with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Attentional deficits affect activities of daily living in dementia-associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Parkinson's disease. Cognitive changes in relation to treatment response

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

An effect of dopamine depletion on decision-making: the temporal coupling of deliberation and execution

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Inhibition of ongoing responses in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Impairments of mental rotation in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Visuospatial memory deficits at different stages of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Effect of dopaminergic medications on the time course of explicit motor sequence learning in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Motivation, reward, and Parkinson's disease: influence of dopatherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Association of dopamine agonist use with impulse control disorders in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

A neostriatal habit learning system in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Procedural learning and neostriatal dysfunction in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Cortico-striatal contributions to feedback-based learning: converging data from neuroimaging and neuropsychology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Anatomy of a decision: striato-orbitofrontal interactions in reinforcement learning, decision making, and reversal

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Reversal learning in Parkinson's disease depends on medication status and outcome valence.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

By carrot or by stick: cognitive reinforcement learning in parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Getting formal with dopamine and reward

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Enhanced frontal function in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Impaired dimensional selection but intact use of reward feedback during visual discrimination learning in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Characterizing rule-based category learning deficits in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Information-integration category learning in patients with striatal dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Cholinergic deficiency and frontal dysfunction in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Cholinergic-dependent cognitive deficits in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

A subcortico-cortical cholinergic system is affected in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Brain muscarinic receptor subtypes are differently affected in Alzheimer's disease and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Neural bases of set-shifting deficits in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

The effect of dopamine depletion from the caudate nucleus of the common marmoset (Callithrix jacchus) on tests of prefrontal cognitive function.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

The role of learned irrelevance in attentional set-shifting impairments in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Learning and cognitive flexibility: frontostriatal function and monoaminergic modulation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Morphological alterations of the synapses in the locus coeruleus in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Cognitive deficits in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Clinical diagnostic criteria for dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Dementia and survival in Parkinson disease: a 12-year population study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Prognosis of Parkinson Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Risk factors for incident dementia in England and Wales: The Medical Research Council Cognitive Function and Ageing Study. A population-based nested case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Commentary: DLB and PDD: the same or different? Is there a debate?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Dementia and cognitive impairment in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Recognition memory in Parkinson's disease with and without dementia: evidence inconsistent with the retrieval deficit hypothesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

A modern hypothesis: The distinct pathologies of dementia associated with Parkinson's disease versus Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Neuropsychiatric disturbances in Parkinson's disease clusters in five groups with different prevalence of dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

The effect of age of onset of PD on risk of dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Relationships between age and late progression of Parkinson's disease: a clinico-pathological study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Cognitive Predictors of Dementia in Parkinson’s Disease: A Community-Based, 4-Year Longitudinal Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

1 reference

7 January 2021

The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

A whole-brain analysis in de novo Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Grey matter atrophy in early versus late dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Amygdalar and hippocampal MRI volumetric reductions in Parkinson's disease with dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Regional cerebral blood flow in Parkinson's disease with and without dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Imaging beta-amyloid burden in aging and dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Differences in neuropathologic characteristics across the Lewy body dementia spectrum.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Rivastigmine and Parkinson dementia complex.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Visual hallucination in Parkinson's disease with FDG PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Frontal and associative visual areas related to visual hallucinations in dementia with Lewy bodies and Parkinson's disease with dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Visual perception in Parkinson disease dementia and dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Characterizing clinical phenotypes: the Lewys in their life or the life of their Lewys?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Cholinergic dysfunction in diseases with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Rivastigmine for dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Associations between family history of Parkinson's disease and dementia and risk of dementia in Parkinson's disease: A community-based, longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Familial occurrence of dementia and parkinsonism: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Alpha-synuclein locus duplication as a cause of familial Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Tau gene and Parkinson's disease: a case-control study and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

The k variant of the butyrylcholinesterase gene is associated with reduced phosphorylation of tau in dementia patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Understanding the dopaminergic deficits in Parkinson's disease: insights into disease heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Cognitive deficits and striato-frontal dopamine release in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

D(1) receptors in prefrontal cells and circuits

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Changes in motor subtype and risk for incident dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Clarifying the pathological progression of Parkinson’s disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Current pharmacotherapeutic treatment options in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Parkinson's disease and dopaminergic therapy--differential effects on movement, reward and cognition

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Prospective prevalence of pathologic gambling and medication association in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Hallucinations in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

When a Parkinson's disease patient starts to hallucinate

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Pramipexole in comparison to l-dopa: a neuropsychological study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Pergolide effect on cognitive functions in early-mild Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Association between amantadine and the onset of dementia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Cholinesterase inhibitors for Parkinson's disease dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Cognitive rehabilitation in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970212-X

7 January 2021

10.1016/S1474-4422(10)70212-X

Identifiers

DOI

1 reference

release_ite76pyekbe5fd6jfsk5j2x6kq

23 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ite76pyekbe5fd6jfsk5j2x6kq

24 November 2022

mapped directly with Wikidata item

PubMed ID

20880750

1 reference

PubMed ID

20880750